Stealth BioTherapeutics is an AI-driven polypharmacology company focused on drug discovery and development, particularly in mitochondrial diseases
Stealth BioTherapeutics is an AI-driven polypharmacology company focused on drug discovery and development, particularly in mitochondrial diseases. Its lead product, elamipretide, received FDA approval in 2025 for treating Barth syndrome. The company continues to develop new compounds for neurological and cardiac diseases.